Mythocondro®, the Non-Animal CS: efficacy at 600 mg

July 20th, 2018

Knee Osteoarthritis (OA) represents an important cause of disability among adults of 60 years of age or more.

Recently, a randomized, double blind, placebo-controlled clinical trial has been conducted in humans to assess the efficacy and safety of a low-dose of non-animal CS - as Mythocondro® - in treating subjects with knee OA.

The study involved 60 subjects, males and females, overweight (BMI > 25 kg/m2), aged 40–74, with mobility impairment, joint discomfort or established moderate knee OA (classification 1-3 according to Kellgren and Lawrence system for classification of knee OA), pain intensity measured using the Visual Analogue Scale (VAS) with a value of 40-70 mm, Lequesne Index of 6-10. They were divided into two groups: 30 of them received one tablet of 600 mg of Mythocondro® each day for 12 weeks, the other 30 were provided with a placebo.

Primary endpoints included the evaluation of knee function by the scientifically recognized WOMAC (Western Ontario and McMaster Universities Arthritis) Index, consisting in five questions that assess pain while walking on a flat surface, going up or down stairs, in bed at night, sitting or lying, and standing upright.

The decrease in WOMAC score in the group treated with Mythocondro® (-21.95%), versus  WOMAC increase in the placebo group (+7,93%), demonstrates significant improvement in knee function.